AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01013129 — intervention group
Intervention type: PROCEDURE
Intervention: evaluation of cancer risk factors
Description: pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
Study NCT01013129 — intervention group
Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: prostate biopsy pathology reports will be reviewed for high risk factors
Study NCT04393415 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: giving stem cells to patients with covid - 19
Study NCT02831764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
Study NCT02831764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
Study NCT02831764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Description: Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
Study NCT02831764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Description: Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SARILUMAB
Description: Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
Study NCT03449758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT02232022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ Insertable Cardiac Monitor
Study NCT03798717 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heating
Description: Warm water immersion
Study NCT00942903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provox Xtra HME
Description: Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
Study NCT00884364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
Study NCT00884364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue counseling
Description: The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
Study NCT04380506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Drains Management
Description: The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
Study NCT03314493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25Mg Tablet
Description: Patients with coronary calcium score > 30 were treated with spironolactone for 12 months
Study NCT01804478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mild pneumatic compression
Study NCT01609348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule matching active drug to be taken once a day for 12 weeks
Study NCT01609348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: 225 mg daily for 12 weeks
Study NCT00101231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT04381858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma from COVID-19 convalescent patient
Description: Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title > 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction.
Study NCT04381858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human immunoglobulin
Description: Human immunoglobulin 0.3 gr/kg/day (5 doses)
Study NCT03714178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE Endocardial Ablation System
Description: Endocardial ablation using the FARAPULSE Endocardial Ablation System.
Study NCT01803425 — intervention group
Intervention type: OTHER
Intervention: Synflorix™ data collection
Description: Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
Study NCT01808196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
Study NCT03588663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline Bionic Leg Assessment
Description: The 'Bionic Leg' (BL) \[Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014\], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
Study NCT03588663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Control Condition Assessment
Description: Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
Study NCT03588663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
Study NCT03588663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Assessment
Description: 45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
Study NCT00985673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections
Study NCT00985673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections
Study NCT00985673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection
Study NCT00985673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection
Study NCT04760756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragility Fracture Integrated Rehabilitation Management
Description: * At least 2 hours of rehabilitation management per day~* Including occupational therapy (training to improve daily life performance)~* Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~* Outpatient (2-6 weeks): management once a week~* The management period is for 2 weeks (1 week after surgery)
Study NCT00974142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
Study NCT00974142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifteen patients will receive will receive placebo.
Study NCT03715517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous thoracic epidural analgesia
Description: Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose
Study NCT03715517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with intrathecal morphine
Description: Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in \<5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid
Study NCT03715517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% in Dextrose Inj 8.25%
Description: 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
Study NCT03715517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
Study NCT03715517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Preservative-Free Injectable Solution
Description: 0.25 mg⋅kg-¹ bupivacaine 0.25%
Study NCT03715517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupicavaine 0.125% epidural solution
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
Study NCT03715517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 10 mcg/mL epidural solution
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
Study NCT00531284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
Study NCT00531284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally or by IV infusion prior to carfilzomib
Study NCT00291135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg daily
Study NCT03057496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collision warning device
Description: The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
Study NCT01100866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: POMELLA™ (pomegranate extract)
Description: in a capsule form, 2 x 500mg once daily
Study NCT01100866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study NCT00989001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant
Description: Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
Study NCT00989001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection
Study NCT04735835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
Study NCT00786383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B
Description: Cohort 1~6 mg/kg I.V., once every other week for 4 weeks
Study NCT00786383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 2~8mg/kg I.V., once every other week for 4 weeks
Study NCT00786383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 3~10 mg/kg I.V., once every other week for 4 weeks
Study NCT00786383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks
Study NCT00786383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks
Study NCT02136979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: group of patients with propofol-based anesthesia
Study NCT02136979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: group of patients with sevoflurane-based anesthesia
Study NCT02160756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-56021927 Softgel Capsule
Description: Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
Study NCT02160756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 Tablet Formulation 1
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
Study NCT02160756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 Tablet Formulation 2
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
Study NCT02160756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 Tablet Formulation 3
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
Study NCT04070781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles
Study NCT04070781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles
Study NCT02264275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
Study NCT04617782 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Transdermal Delivery System
Study NCT04617782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Oral
Study NCT00379847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV
Study NCT03416088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage consumption
Description: The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
Study NCT03416088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily reading
Description: Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
Study NCT03416088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body motion
Description: Exercise or body postural changes
Study NCT01307319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA
Description: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
Study NCT01307319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal aerosol
Description: Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
Study NCT03494868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Drink
Description: 2 - 12 oz drinks
Study NCT02413918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
Study NCT03973216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A primary care group-based therapeutic yoga program
Description: The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
Study NCT01476059 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone follow-up
Description: Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.